Press releaseGlobe Newswire
Liminatus Pharma
LIMN · NASDAQ
$3.22+$0.11 (+3.54%)TodayMarket closed ·
Prev close $3.11
Latest news
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releaseGlobe Newswire
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- Press releaseGlobe Newswire
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- NewsAvi Kapoor
Dow Gains Over 250 Points; US Jobs Rise By 57,000 In June
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- NewsMohd Haider
Liminatus Pharma (LIMN) Stock Is Trending Overnight — Here’s Why it Spiked Over 30% in After-Hours Session (UPDATED)
- Press releaseGlobe Newswire
Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- Press releaseGlobe Newswire
Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds
- NewsCaroline Ryan
Deal Dispatch: IMAX Mulls Potential Sale, Shein Buys Everlane, West Marine Bankruptcy
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsAvi Kapoor
Crude Oil Moves Higher; Walmart Shares Fall After Q1 Results
- NewsAvi Kapoor
US Stocks Lower; Nvidia Posts Upbeat Earnings
- News
Liminatus Pharma Entered Definitive Agreement To Acquire InnocsAI On May 17 In $320M All-Stock Transaction
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releaseGlobe Newswire
Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline
- NewsMohd Haider
Liminatus Pharma Is Trending Overnight — Here's Why LIMN Stock Surged Over 79% In After-Hours Session
- Press releaseGlobe Newswire
Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody
- NewsAvi Kapoor
Gold Down 3%; Medtronic Earnings Top Views
- NewsAvi Kapoor
US Stocks Mixed; NY Manufacturing Activity Falls In February
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- NewsAvi Kapoor
Dow Surges Over 200 Points; BJ's Wholesale Posts Upbeat Q3 Earnings
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releaseGlobe Newswire
Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation
- Press releaseGlobe Newswire
Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- NewsRishabh Mishra
US Stocks Likely To Open Higher: S&P 500 Sees 'Average Gain Of 6.1%' In 2nd Half, Expert Says
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsAvi Kapoor
Kroger Posts Better-Than-Expected Earnings, Joins Couchbase, CarMax And Other Big Stocks Moving Higher On Friday
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.